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To determine whether health-related quality of life (HRQOL) scores improved or worsened over 
3 years of observation in childhood intermittent exotropia without treatment.  
Methods 
A total of 111 children aged 3-11 years with intermittent exotropia were assigned to observation 
in a previously reported randomized trial comparing patching with observation. The intermittent 
exotropia questionnaire (IXTQ) was administered at baseline, 6 months, and 36 months. Rasch-
calibrated IXTQ domain scores (Child, Proxy, Parent-psychosocial, Parent-function, and Parent-
surgery) were compared between time points. The Child IXTQ was administered only to children 
≥5 years of age (n = 78).  
Results 
Overall, Child IXTQ and Proxy IXTQ scores showed no significant change over 36 months 
(mean improvement from baseline to 36 months of 3.2 points [95% CI, −1.9 to 8.2] and −2.4 
points [95% CI: −7.9 to 3.1], resp.). By contrast, Parent-psychosocial, Parent-function, and 
Parent-surgery domain scores all improved over 36 months (mean improvements of 12.8 points 
[95% CI, 5.9-19.6] and 14.2 points [95% CI, 8.0-20.3] and 18.5 points [95% CI, 9.7-27.3], 
resp.). 
Conclusions 
HRQOL of children with intermittent exotropia remains stable with observation over 3 years (by 
both child and proxy report), whereas parental HRQOL improves. 
Intermittent exotropia is one of the most common types of childhood strabismus, affecting 
approximately 0.6% of all children.1 The Intermittent Exotropia Questionnaire (IXTQ)2 was 
designed specifically to evaluate health-related quality of life (HRQOL) in children with 
intermittent exotropia and their parents. The IXTQ has three components: Child, Proxy (parent 
perception of the effect on their child), and Parent. The Parent IXTQ assesses the effect on the 
parent and family in three domains: Parent-psychosocial (parental concerns regarding the effect 
on the child’s social interactions), Parent-function (parental concerns regarding the child’s 
function), and Parent-surgery (parental concerns regarding the prospect of potential surgery for 
their child).2 Example items in the Parent domains are “I worry about how my child’s eyes will 
affect him/her socially” (Psychosocial), “I worry that my child doesn’t see well” (Function), and 
“I worry about the possibility of surgery” (Surgery). The complete questionnaires and scoring 
algorithm are available at https://public.jaeb.org/pedig/view/Reference. The purpose of the 
present study was to determine whether health-related quality of life (HRQOL) scores improved 
or worsened over 3 years of observation in childhood intermittent exotropia without treatment.  
Subjects and Methods 
In a previously reported randomized controlled trial (www.clinicaltrials.gov: NCT 01032330; 
full protocol available at https://public.jaeb.org/pedig/stdy/154)3 children with intermittent 
exotropia were assigned to either part-time patching (required for 5 months and at investigator 
discretion after 6 months) or observation and then subsequently followed for 3 years. The 
original study3 from which these data were derived was supported through a cooperative 
agreement with the National Eye Institute of the National Institutes of Health and conducted 
according to the tenets of the Declaration of Helsinki by PEDIG at academic- and community-
based sites. Health Insurance Portability and Accountability Act–compliant informed consent 
forms and study protocols were approved by institutional review boards. A parent or guardian 
(henceforth, “parent”) provided written informed consent, and children gave written assent when 
required by the local institutional review board, typically age 7 years and above.  
Clinical outcomes for the observation cohort after 3 years of follow-up have been 
reported previously.4 For the current report, analyses were limited to children 5 to <11 years of 
age (old enough for questionnaires to be completed) and parents of children aged 3 to <11 years 
of age who completed questionnaires at baseline. Participants included for analysis at each time 
point and reasons for exclusion are shown in eSupplement 2 (available at jaapos.org).  
The IXTQ was completed by participants and one of their parents at baseline 
(enrollment), 6 months (window, 5-7 months), and 36 months (window, 34-38 months). 
Participants ≥5 years of age completed the 12-item Child IXTQ, administered by study personnel 
for 5- to 7-year-old children and self-administered for children 8 years and older, with help from 
study personnel if needed. Children 5-7 years of age completed the Child IXTQ using a 3-point 
Likert scale (“Not at all,” “Sometimes,” “A lot”), while a 5-point scale was used for children ≥8 
years old (“Never,” “Almost Never,” “Sometimes,” “Often,” “Almost Always”). All parents 
were asked to self-complete the 12-item Proxy IXTQ (parental assessment of their child’s 
HRQOL) and the 17-item Parent IXTQ questionnaire. Both Proxy and Parent questionnaires 
used the 5-point response scale.  
IXTQ responses to each question were converted to Rasch-based logit scores using IXTQ 
Rasch lookup tables (https://public.jaeb.org/pedig/view/reference, accessed 9/1/2020)5 and 
averaged to obtain a participant-level score for each domain (Child, Proxy, Parent-psychosocial, 
Parent-function, and Parent-surgery). The raw Rasch scores (logit values) were analyzed to 
obtain p-values but, to aid in interpretation, participant-level scores were converted to a 0 (worst) 
to 100 (best) scale for reporting group means and confidence intervals. HRQOL scores were 
compared between baseline and 6 months, and between baseline and 36 months, using Wilcoxon 
signed rank tests due to a non-normal distribution. Rasch scores from the respective age-
appropriate version of the Child IXTQ (5 to <8-year-old version and ≥8-year-old version) were 
used for analysis. Rasch scores from the ≥8-year-old version of the questionnaire were scaled to 
match the range of the younger questionnaire.  
All P values and 95% confidence intervals were adjusted for multiplicity using the 
Stepdown Bonferroni method,6 with analyses grouped to control the type 1 error rate at the 5% 
level. No imputation was performed for missing data. Analyses were conducted using SAS 
version 9.4 (SAS Institute Inc, Cary, NC).  
Results 
From baseline to 6 months and from baseline to 36 months, the Child IXTQ and Proxy IXTQ 
scores showed no significant change (Table 1 and Figure 1). In contrast, the Parent-function and 
Parent-psychosocial domain scores improved over the same time periods with observation, 
whereas Parent-surgery domain scores improved from baseline to 36 months. 
Discussion 
Comparing our results with previous studies, Clarke and colleagues7 reported longitudinal Child, 
Proxy, and Parent IXTQ data (baseline and 9 months follow-up) in a pilot randomized trial 
comparing active monitoring (observation, n = 20 with follow-up) with surgery (n = 25). With 
observation, they found no significant change in score on any IXTQ domain.7 Our current results 
are consistent for the Child and Proxy domains (at our time points of 6 and 36 months), but we 
found improvement in Parent IXTQ scores at both 6 and 36 months. It is possible that 
differences in results might be attributable to Clarke’s smaller sample size, our longer follow-up, 
or difference in comparison group in each of the studies (observation vs surgery in the study of 
Clarke and colleagues, whereas observation vs patching in the present study).  
The stability of Child or Proxy IXTQ scores and improvement of Parent IXTQ scores is 
possibly related to the low frequency of clinical deterioration of intermittent exotropia in these 
children who were observed over this 36-month period.4 In this population, there was a mean 
improvement (over 36 months) in distance and near stereoacuity, distance control, and 
magnitude of distance exodeviation.4 Moreover, when we applied a definition of “resolution or 
near resolution” (exodeviation <10Δ at distance and near, no reduction in stereoacuity, and no 
other nonsurgical treatment for intermittent exotropia)8 we found 6 (7%) of the current observed 
cohort met these criteria at 36 months. Another reason why the Child or Proxy IXTQ scores 
remained stable and the Parent IXTQ scores improved over this 36-month period, is that parents 
may have become less anxious about the condition with time, and there may have been an effect 
of counselling by the treating provider and study coordinators, who may have provided positive 
feedback to the family during the 36-month period of observation.  
Our study has some limitations. Our cohort may have had somewhat less severe 
intermittent exotropia than an unselected cohort, because a simultaneous surgical study was 
being conducted by the same investigator group.9 In the original RCT from which the current 
IXTQ data was derived, the mean magnitude of distance exodeviation in the Observation group 
was 23Δ by prism and alternate cover test and the mean distance control was 2.4 points,3 and 
therefore caution should be taken extrapolating the current IXTQ data to more severe cases of 
intermittent exotropia. Although there was possibly a component of regression to the mean, we 
did not enroll based on any IXTQ threshold. We did not have complete follow-up (80% at 3 
years) and we excluded participants who received treatment over the course of the study (n = 
15). We did not compare IXTQ scores in the observed cohort with those who were randomized 
to patching in the original RCT,3 because those who underwent patching were instructed to stop 
patching one month before initial 6-month outcome examination and were released to patching 
treatment at investigator discretion after the 6-month examination.  
In conclusion, HRQOL of children remains stable with observation of intermittent 
exotropia over 3 years (by both child and proxy report), whereas parental HRQOL improves. 
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FIG 1. IXTQ scores at baseline, 6 months, and 36 months. A, Child IXTQ. B, Proxy IXTQ. C, 
Parent-psychosocial IXTQ. D, Parent-function IXTQ. E, Parent-surgery IXTQ. The center line of 
each box represents the median domain score, the boundary of each box represents 25th and 75th 
percentiles, and the whiskers represent the extreme values. The diamond within each box 
represents the mean value. 
Table 1. IXTQ scores at baseline, 6 months, and 36 months for untreated Intermittent exotropia   
 
Study parameter Baseline 6 months 36 months 
Child IXTQ, no. 78 70 62 
Median (IQR) 77.3 (68.1, 90.9) 86.4 (72.7, 95.4) 86.3 (72.7, 95.4) 
Mean ± SD 78.3 ± 16.6 81.6 ± 17.1 83.0 ± 15.6 
Median change from baseline (IQR)a — 2.3 (−4.6, 9.1) 0.0 (−9.1, 13.6) 
P value for change from baselineb,c — 0.92 1.0 
Mean change from baseline (adjusted 95% CI)a,b — 2.7 (−2.2, 7.7) 3.2 (−1.9, 8.2) 
Proxy IXTQ, no. 111 101 86 
Median (IQR) 81.8 (68.2, 95.5) 81.8 (68.2, 90.9) 81.8 (63.6, 95.5) 
Mean ± SD 78.0 ± 20.2 79.7 ± 16.7 76.6 ± 19.8 
Median change from baseline (IQR)a — 0.0 (−9.1, 9.1) 0.0 (−9.1, 4.6) 
P value for change from baselineb,c — 1.0 1.0 
Mean change from baseline (adjusted 95% CI)a,b — 1.2 (−3.6, 6.0) −2.4 (−7.9, 3.1) 
Parent psychosocial IXTQ, no.  111 101 86 
Median (IQR) 71.5 (50.4, 89.2) 79.2 (63.9, 96.5) 84.4 (70.8, 96.5) 
Mean ± SD 67.1 ± 26.1 76.1 ± 23.2 80.2 ± 22.0 
Median change from baseline (IQR)a — 3.5 (−3.5, 21.5) 5.9 (0.0, 28.1) 
P value for change from baselineb,c — 0.004 <0.0001 
Mean change from baseline (adjusted 95% CI)a,b — 8.2 (1.5, 14.9) 12.8 (5.9, 19.6) 
Parent function IXTQ   111 101 86 
Median (IQR) 61.3 (48.9, 74.4) 69.6 (60.6, 83.4) 79.3 (64.0, 91.7) 
Mean ± SD 60.4 ± 21.1 70.1 ± 19.9 75.6 ± 19.6 
Median change from baseline (IQR)a — 6.2 (−1.4, 20.0) 12.8 (2.8, 25.0) 
P value for change from baselineb,c — <0.0001 <0.0001 
Mean change from baseline (adjusted 95% CI)a,b — 8.8 (3.6, 14.0) 14.2 (8.0, 20.3) 
PARENT surgery IXTQ 111 101 86 
Median (IQR) 54.2 (37.7, 77.1) 68.7 (54.2, 83.2) 83.2 (54.2, 100.0) 
Mean ± SD 56.9 ± 26.4 65.4 ± 25.8 75.0 ± 23.6 
Median change from baseline (IQR)a — 0.0 (0.0, 21.1) 16.7 (0.0, 33.2) 
P value for change from baselineb,c — 0.06 <0.0001 
Mean change from baseline (adjusted 95% CI)a,b — 7.3 (0.1, 14.4) 18.5 (9.7, 27.3) 
CI, confidence interval; IQR, interquartile range; IXTQ, Intermittent Exotropia Questionnaire; SD, standard deviation. 
aPositive values for change indicate improvement. 
bP value for change from baseline calculated on raw Rasch scores using the Wilcoxon signed-rank test; P values 
adjusted for multiple testing using the stepdown-Bonferroni method to control type I error rate at 5%. 
cCIs adjusted for multiple testing using the stepdown-Bonferroni method to control type I error rate at 5%. 

